X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5248) 5248
Book Review (618) 618
Publication (371) 371
Newsletter (70) 70
Book Chapter (37) 37
Magazine Article (10) 10
Conference Proceeding (6) 6
Newspaper Article (6) 6
Dissertation (2) 2
Government Document (2) 2
Book / eBook (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4512) 4512
humans (2758) 2758
animals (2183) 2183
male (1684) 1684
lactones - pharmacology (1457) 1457
female (1232) 1232
pharmacology & pharmacy (1073) 1073
lactones (940) 940
lactones - therapeutic use (935) 935
rats (828) 828
mice (709) 709
adult (619) 619
middle aged (553) 553
lactones - chemistry (520) 520
lactones - adverse effects (493) 493
biochemistry & molecular biology (479) 479
analysis (474) 474
lactones - administration & dosage (409) 409
chemistry, medicinal (408) 408
sesquiterpene lactones (389) 389
research (379) 379
aged (361) 361
ginkgolides (344) 344
abridged index medicus (338) 338
orlistat (333) 333
anti-obesity agents - therapeutic use (324) 324
dose-response relationship, drug (320) 320
apoptosis (311) 311
cancer (309) 309
diterpenes (309) 309
obesity - drug therapy (308) 308
sulfones (301) 301
expression (286) 286
sesquiterpenes - pharmacology (284) 284
in-vitro (276) 276
obesity (274) 274
rats, sprague-dawley (261) 261
inhibition (260) 260
time factors (253) 253
treatment outcome (252) 252
oncology (248) 248
rofecoxib (247) 247
plant extracts - pharmacology (245) 245
platelet activating factor - antagonists & inhibitors (241) 241
inflammation (238) 238
pharmacokinetics (236) 236
chemistry, analytical (234) 234
health aspects (233) 233
microbiology (233) 233
cells (225) 225
lactones - metabolism (225) 225
double-blind method (223) 223
celecoxib (219) 219
care and treatment (218) 218
drugs (218) 218
cell line, tumor (217) 217
lactone (216) 216
immunology (214) 214
plant sciences (212) 212
lactones - blood (209) 209
article (208) 208
nf-kappa-b (208) 208
cell biology (207) 207
proteins (205) 205
physiological aspects (201) 201
risk factors (200) 200
lactones - pharmacokinetics (199) 199
molecular structure (198) 198
rats, wistar (197) 197
nonsteroidal antiinflammatory drugs (194) 194
cells, cultured (193) 193
drug therapy (191) 191
parasitology (188) 188
cyclooxygenase 2 (186) 186
apoptosis - drug effects (184) 184
disease models, animal (182) 182
toxicology (181) 181
antineoplastic agents - pharmacology (179) 179
oxidative stress (179) 179
mass spectrometry (178) 178
medicine, general & internal (177) 177
cell line (176) 176
cyclooxygenase inhibitors - adverse effects (176) 176
endocrinology & metabolism (176) 176
weight loss (176) 176
cyclooxygenase 2 inhibitors (174) 174
metabolites (174) 174
adolescent (173) 173
quorum sensing (172) 172
macrolides (171) 171
in vitro techniques (170) 170
enzymes (168) 168
dogs (166) 166
kinetics (161) 161
anti-inflammatory agents, non-steroidal - adverse effects (160) 160
chemistry, multidisciplinary (160) 160
activation (159) 159
biochemical research methods (159) 159
enzyme inhibitors - pharmacology (159) 159
structure-activity relationship (159) 159
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5151) 5151
German (105) 105
Chinese (29) 29
Russian (18) 18
French (13) 13
Japanese (13) 13
Spanish (9) 9
Italian (7) 7
Polish (5) 5
Czech (2) 2
Hungarian (2) 2
Korean (2) 2
Ukrainian (2) 2
Danish (1) 1
Serbian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 12/2007, Volume 5, Issue 12, pp. 2376 - 2385
Background:  Selective inhibitors of cyclooxygenase‐2 (COX‐2) called coxibs, are effective anti‐inflammatory and analgesic drugs. Recently, these drugs were... 
thromboxane | coxibs | thrombin generation | prostacyclin | NSAID | platelet activation | Thrombin generation | Prostacyclin | Platelet activation | Thromboxane | Coxibs | MASS-SPECTROMETRY | CYCLOOXYGENASES | ANTIPLATELET | THROMBOMODULIN | CLOPIDOGREL | PERIPHERAL VASCULAR DISEASE | HEMATOLOGY | EXPRESSION | IONIZATION | TISSUE FACTOR | Humans | Naproxen - pharmacology | Sulfones - adverse effects | Male | Reference Values | Blood Platelets - enzymology | Sulfones - pharmacology | Prostaglandins - blood | Lactones - pharmacology | Phospholipases A - blood | Cyclooxygenase 2 Inhibitors - adverse effects | Sulfonamides - blood | Lactones - blood | Cyclooxygenase 2 - blood | Time Factors | Prostaglandins - urine | Pyrazoles - blood | Antigens, Neoplasm - blood | Adult | Platelet Aggregation - drug effects | Cyclooxygenase 2 Inhibitors - blood | Blood Platelets - drug effects | Sulfones - blood | Pyrazoles - adverse effects | Pyrazoles - pharmacology | Thrombomodulin - blood | Naproxen - adverse effects | Cyclic AMP - blood | Cyclooxygenase 2 Inhibitors - pharmacology | Double-Blind Method | Celecoxib | Lactones - adverse effects | Cell Adhesion - drug effects | Naproxen - blood | Sulfonamides - pharmacology | Thromboxanes - blood | Thromboxanes - urine | Blood Platelets - metabolism | Fibrinogen - metabolism | P-Selectin - blood | Sulfonamides - adverse effects | Leukocytes - drug effects | Platelet Activation - drug effects | Thrombin - metabolism | Platelet Membrane Glycoprotein IIb - blood | Physiological aspects | Prothrombin | COX-2 inhibitors | Thrombin | Analysis | Index Medicus
Journal Article
Journal Article
FASEB Journal, ISSN 0892-6638, 03/2006, Volume 20, Issue 3, pp. 542 - 544
It is widely believed that the potencies of nonsteroid anti-inflammatory drugs ( NSAIDs) as inhibitors of cyclooxygenase ( COX) are influenced by protein... 
SITE | MECHANISM | BIOCHEMISTRY & MOLECULAR BIOLOGY | nonsteroid anti-inflammatory drugs | coxibs | PROSTAGLANDIN H-2 SYNTHASE | CELL BIOLOGY | CYCLO-OXYGENASE-2 | THERAPY | FLUID | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | BIOLOGY | prostaglandins | SELECTIVITY | Organic Chemicals - cerebrospinal fluid | Humans | Naproxen - pharmacology | Synovial Fluid - metabolism | Pyrazoles - cerebrospinal fluid | Sodium Salicylate - pharmacology | Lactones - pharmacology | Aspirin - cerebrospinal fluid | Cell Line - drug effects | Calcium - physiology | Pyrazoles - blood | Organic Chemicals - pharmacology | Dinoprostone - cerebrospinal fluid | Diclofenac - cerebrospinal fluid | Aspirin - pharmacology | Sulfones - cerebrospinal fluid | Aspirin - blood | Thiazines - blood | Sulfonamides - pharmacology | Indomethacin - cerebrospinal fluid | Indomethacin - pharmacology | Cyclooxygenase 1 - drug effects | Cyclooxygenase Inhibitors - adverse effects | Cyclooxygenase Inhibitors - blood | Diclofenac - pharmacology | Thiazoles - blood | Thromboxane A2 - blood | Cerebrospinal Fluid Proteins - pharmacology | Dinoprostone - biosynthesis | Lactones - cerebrospinal fluid | Blood Platelets - enzymology | Cyclooxygenase 2 Inhibitors - cerebrospinal fluid | Sodium Salicylate - cerebrospinal fluid | Sulfones - pharmacology | Blood Proteins - pharmacology | Cyclooxygenase 2 Inhibitors - adverse effects | Sulfonamides - blood | Lactones - blood | Naproxen - cerebrospinal fluid | Sodium Salicylate - blood | Thiazines - pharmacology | Cyclooxygenase 2 Inhibitors - blood | Cyclooxygenase Inhibitors - cerebrospinal fluid | Blood Platelets - drug effects | Sulfones - blood | Organic Chemicals - blood | Ionophores - pharmacology | Pyrazoles - pharmacology | Sulfonamides - cerebrospinal fluid | Cyclooxygenase 2 Inhibitors - pharmacology | Thiazoles - cerebrospinal fluid | Celecoxib | Diclofenac - blood | Dinoprostone - blood | Naproxen - blood | Organ Specificity | Calcimycin - pharmacology | Cyclooxygenase Inhibitors - pharmacology | Indomethacin - blood | Protein Binding | Thiazines - cerebrospinal fluid | Thiazoles - pharmacology | Index Medicus
Journal Article
Journal Article
Journal Article
Molecular Nutrition & Food Research, ISSN 1613-4125, 12/2017, Volume 61, Issue 12, pp. 1700294 - n/a
To understand the mechanism by which green tea lowers the risk of dementia, metabolites of epigallocatechin gallate (EGCG) are focused on. The in vitro... 
5‐(3′,5′‐dihydroxyphenyl)‐γ‐valerolactone | blood–brain barrier | green tea catechin | EGCG | nerve cell proliferation/differentiation | 5-(3′,5′-dihydroxyphenyl)-γ-valerolactone | blood-brain barrier | REGRESSION | FOOD SCIENCE & TECHNOLOGY | RATS | AGED MICE | TANDEM MASS-SPECTROMETRY | EXCRETION | 5-(3 ',5 '-dihydroxyphenyl)-gamma-valerolactone | POLYPHENOLS | (-)-EPIGALLOCATECHIN GALLATE | ABSORPTION | CONSUMPTION | Humans | Blood-Brain Barrier - drug effects | Pyrogallol - pharmacokinetics | Lactones - pharmacokinetics | Cell Differentiation - drug effects | Neuroblastoma - drug therapy | Cell Line, Tumor | Catechin - analogs & derivatives | Cell Proliferation - drug effects | Neuroblastoma - metabolism | Catechin - metabolism | Catechin - pharmacokinetics | Catechin - pharmacology | Neurites - drug effects | Tea - chemistry | Catechin | Metabolites | Neurons | Analysis | Liquid chromatography | Neuroblastoma | Permeability | Sulfates | Mass spectrometry | Green tea | Dementia | Cell proliferation | Membrane permeability | Parenchyma | Neurogenesis | Cell growth | Blood-brain barrier | Animal tissues | Dementia disorders | Gallic acid | Axonogenesis | Epigallocatechin-3-gallate | Rats | Mass spectroscopy | Pyrogallol | Tea | Axons | Epigallocatechin gallate | Sulfate | In vitro methods and tests | Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 9/2010, Volume 107, Issue 39, pp. 17017 - 17022
Chronic administration of high levels of selective COX-2 inhibitors (coxibs), particularly rofecoxib, valdecoxib, and parecoxib, increases risk for... 
Metabolomics | Blood coagulation | Metabolites | Coagulation | Mice | Platelet aggregation | Bleeding time | Platelets | Blood | Blood plasma | Eicosanoids | Coxib | Vioxx | Cardiovascular side effect | coxib | MULTIDISCIPLINARY SCIENCES | ENDOTHELIUM-DEPENDENT VASOCONSTRICTOR | 20-HYDROXYEICOSATETRAENOIC ACID | RISK | TOXICITY | INCREASED PLATELET AGGREGABILITY | CORONARY HEART-DISEASE | 20-HETE CONTRIBUTES | eicosanoids | metabolomics | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | cardiovascular side effect | ACUTE MYOCARDIAL-INFARCTION | EPOXIDE HYDROLASE INHIBITORS | Cyclooxygenase 2 Inhibitors - administration & dosage | Mice, Inbred C57BL | Sulfones - adverse effects | Male | Biomarkers - blood | Lactones - adverse effects | Hydroxyeicosatetraenoic Acids - blood | Cyclooxygenase 2 Inhibitors - adverse effects | Animals | Blood Coagulation - drug effects | Hydroxyeicosatetraenoic Acids - pharmacology | Lactones - administration & dosage | Cardiovascular Diseases - blood | Bleeding Time | Cardiovascular Diseases - chemically induced | Platelet Aggregation - drug effects | Blood Platelets - drug effects | Cardiovascular Diseases - diagnosis | Sulfones - administration & dosage | Metabonomic analysis | COX-2 inhibitors | Care and treatment | Physiological aspects | Dosage and administration | Research | Cardiovascular diseases | Biological markers | Methods | Biomarkers | Cardiovascular disease | Pharmacology | Nonsteroidal anti-inflammatory drugs | Rodents | Risk factors | Index Medicus | Animal models | biomarkers | Oral administration | Data processing | Bleeding | Clotting | Blood levels | Cost-benefit analysis | rofecoxib | Cytochromes | Cyclooxygenase-2 | Biological Sciences
Journal Article
Nutrition, Metabolism and Cardiovascular Diseases, ISSN 0939-4753, 2009, Volume 19, Issue 9, pp. 626 - 633
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 08/2016, Volume 14, Issue 8, pp. 1642 - 1654
Journal Article
Journal Article
Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 10/2006, Volume 33, Issue 10, pp. 917 - 924
SUMMARY • Non-steroidal anti-inflammatory drugs (NSAIDs) cause renal side-effects. In the present study, we tested the hypothesis that the extent of the renal... 
pharmacokinetics | kidney | non-steroidal anti-inflammatory drugs | cyclo-oxygenase-2 | sodium urinary excretion | cyclo‐oxygenase‐2 | non‐steroidal anti‐inflammatory drugs | Cyclo-oxygenase-2 | Pharmacokinetics | Kidney | Non-steroidal anti-inflammatory drugs | Sodium urinary excretion | GASTROINTESTINAL TOXICITY | PHYSIOLOGY | CYCLOOXYGENASE-2 | RAT | HYPERKALEMIA | PROTEIN-BINDING | MELOXICAM | INTERSPECIES DIFFERENCES | GENTAMICIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PHARMACOLOGY & PHARMACY | Thiazoles - blood | Area Under Curve | Thiazines - administration & dosage | Thiazines - adverse effects | Sulfones - adverse effects | Male | Thiazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - blood | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Sulfonamides - blood | Lactones - blood | Lactones - pharmacokinetics | Sodium - urine | Lactones - administration & dosage | Pyrazoles - blood | Pyrazoles - pharmacokinetics | Sulfones - blood | Placebos - administration & dosage | Pyrazoles - adverse effects | Thiazines - pharmacokinetics | Kidney - drug effects | Administration, Oral | Cyclooxygenase 2 Inhibitors - administration & dosage | Rats | Thiazines - blood | Celecoxib | Lactones - adverse effects | Placebos - pharmacokinetics | Sulfones - pharmacokinetics | Cyclooxygenase 2 Inhibitors - pharmacokinetics | Rats, Sprague-Dawley | Sulfonamides - pharmacokinetics | Pyrazoles - administration & dosage | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Potassium - urine | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Kidney, drug effects | Lactones, adverse effects | Sulfones, administration and dosage | Thiazoles, administration and dosage | Anti-Inflammatory Agents, Non-Steroidal, pharmacokinetics | Anti-Inflammatory Agents, Non-Steroidal, adverse effects | Sodium, urine | Thiazines, blood | Anti-Inflammatory Agents, Non-Steroidal, blood | Lactones, administration and dosage | Cyclooxygenase 2 Inhibitors, adverse effects | Pyrazoles, blood | Sulfonamides, pharmacokinetics | Thiazines, pharmacokinetics | Pyrazoles, administration and dosage | Thiazoles, blood | Sulfonamides, administration and dosage | Cyclooxygenase 2 Inhibitors, administration and dosage | Lactones, pharmacokinetics | Sulfonamides, blood | Cyclooxygenase 2 Inhibitors, pharmacokinetics | Thiazines, adverse effects | Lactones, blood | Thiazoles, adverse effects | Thiazoles, pharmacokinetics | Sulfones, blood | Sulfonamides, adverse effects | Thiazines, administration and dosage | Placebos, pharmacokinetics | Sulfones, pharmacokinetics | Pyrazoles, adverse effects | Placebos, administration and dosage | Potassium, urine | Sulfones, adverse effects | Pyrazoles, pharmacokinetics | Index Medicus
Journal Article